Protect Moms From Domestic Violence Act
Summary
S4387, the Protect Moms From Domestic Violence Act, is an early-stage bill introduced in the Senate and referred to committee. It contains no authorized funding, no specific mandates on private sector entities, and no market-moving mechanisms. No actionable market impact exists at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4387 is in the earliest legislative stage—introduced and referred to committee.
- 2.No funding amount, no mandates, and no private sector obligations are specified.
- 3.No market impact is identifiable from the available data.
Market Implications
There are no market implications from this bill at this time. No tickers are affected. Investors should monitor committee activity and any subsequent amendments that introduce specific funding or regulatory mechanisms.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Health Care and Lowering Costs Act of 2025
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
Veterans SPORT Act
American Innovation and R&D Competitiveness Act of 2025
Association Health Plans Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.